Natixis Investment Managers International’s United Therapeutics UTHR Stock Holding History

Natixis Investment Managers International’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,738	Closed	-$222K	–	540
2018 Q3	$222K	Sell	1,738 -144	-8%	-$17.8K	0.01%	597
2018 Q2	$213K	Buy	+1,882	New	+$207K	0.01%	567
2017 Q4	–	Sell	-734	Closed	-$86K	–	344
2017 Q3	$86K	Sell	734 -48	-6%	-$6.13K	0.01%	376
2017 Q2	$101K	Sell	782 -49	-6%	-$6.11K	0.01%	358
2017 Q1	$113K	Buy	831 +35	+4%	+$5.3K	0.01%	345
2016 Q4	$114K	Sell	796 -3,902	-83%	-$498K	0.01%	374
2016 Q3	$555K	Sell	4,698 -1,669	-26%	-$201K	0.06%	247
2016 Q2	$674K	Buy	+6,367	New	+$710K	0.07%	187

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Natixis Investment Managers International's UTHR Position: Q4 2018 in Review

Natixis Investment Managers International sold out of United Therapeutics (UTHR) in Q4 2018, closing a stake of 1,738 shares — an estimated $222K sold.

Natixis Investment Managers International first reported a position in UTHR in Q2 2016 and held it in 8 quarters. The position peaked at $674K in Q2 2016. 360 funds tracked by Wall St. Rank hold UTHR as of Q4 2018.

Natixis Investment Managers International reported no remaining United Therapeutics position as of Q4 2018 after selling out during the quarter.
Natixis Investment Managers International sold 1,738 United Therapeutics shares in Q4 2018, an estimated $222K.
Natixis Investment Managers International first reported a position in United Therapeutics in Q2 2016 and held it in 8 quarters.
Natixis Investment Managers International's United Therapeutics position peaked at $674K in Q2 2016.
360 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2018.

Based on Natixis Investment Managers International's 13F filing for Q4 2018, filed 14 Feb 2019.